Elisabeth Eppard

Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Hojjat Ahmadzadehfar, Kambiz Rahbar, Stefan Kürpig et al. · EJNMMI Research · 2015 · 293 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Hojjat Ahmadzadehfar, Elisabeth Eppard, Stefan Kürpig et al. · Oncotarget · 2016 · 285 citations · Full text

Medicine, Oncology, Pharmacology +17

Response and Tolerability of a Single Dose of¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis

Kambiz Rahbar, Matthias Schmidt, Alexander Heinzel et al. · Journal of Nuclear Medicine · 2016 · 205 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617

Hojjat Ahmadzadehfar, Simone Wegen, Anna Yordanova et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 173 citations

Medicine, Oncology, Pharmacology +17

Clinical Translation and First In-Human Use of [⁴⁴Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer

Elisabeth Eppard, Ana de la Fuente, Martina Benešová et al. · Theranostics · 2017 · 143 citations · Full text

Medicine, Nuclear Medicine, Oncology +17